Drugs / JTE-051
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03358290 | Nov 2017 → Oct 2018 | psoriasis | Akros Pharma Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02919475 | Sep 2016 → Jun 2018 | rheumatoid arthritis | Akros Pharma Inc. | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JTE-051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02919475 ↗ |
| Route | Oral | “One dose of study drug by mouth daily for 12 weeks” NCT02919475 ↗ |